软骨肉瘤化疗耐药机制

doi:10.11904/j.issn.1002-3070.2016.02.018

实用肿瘤学杂志 ›› 2016, Vol. 30 ›› Issue (2): 176-179.doi: 10.11904/j.issn.1002-3070.2016.02.018

软骨肉瘤化疗耐药机制

罗京, 张婷, 黄卉综述, 杨丹审校

哈尔滨医科大学生物化学及分子生物学教研室(哈尔滨 150081)

收稿日期:2016-01-15 出版日期:2016-04-28 发布日期:2016-04-28
通讯作者: 杨丹,E-mail:danyanghmu@163.com
作者简介:罗京,女,(1987-),硕士研究生,从事软骨肉瘤与化学治疗的研究

Sevaral mechanisms of chemoresistance in chondrosarcoma

LUO Jing, ZHANG Ting, HUANG Hui, YANG Dan

Department of Biochemistry and Molecular Biology,Harbin Medical University,Harbin 150081,China

Received:2016-01-15 Online:2016-04-28 Published:2016-04-28

摘要/Abstract

摘要： 软骨肉瘤在国内虽然不是高发疾病,但是软骨肉瘤发病后所造成的后果却足以引起我们的重视。手术治疗的局限性,对放化疗的不敏感,导致病人预后不良。若能克服软骨肉瘤的耐药性,使化学治疗能高效率杀灭肿瘤的同时抑制其侵袭转移的能力,病人的预后会有飞跃性的提高。找到软骨肉瘤的耐药机制是克服软骨肉瘤耐药性及改善预后的关键,因此本文就国内外对软骨肉瘤耐药机制的研究做如下综述。

关键词: 软骨肉瘤, 化疗耐药, 相关因子

Abstract: Chondrosarcomas has low morbidity in China,but we should pay more attention to the Results it contributed to.Patients usually have poor prognosis because of defect of surgical resection and resistance to conventional chemotherapy and radiotherapy.Chemotherapy is a significant method to the chondrosarcoma treatment.If we overcome the difficulty of chemoresistance,chemotherapy will kill the sarcoma cells efficiently and inhibit the capacity of metastasis and invasion.The patients will have better prognosis.Finding the mechanisms of chemoresistance in chondrosarcomas is the key,now we review sevaral recent mechanisms of chemoresistance in chondrosarcoma.

Key words: Chondrosarcoma, Chemoresistance, Relative molecular

中图分类号:

R738.3

罗京, 张婷, 黄卉综述, 杨丹审校. 软骨肉瘤化疗耐药机制[J]. 实用肿瘤学杂志, 2016, 30(2): 176-179.

LUO Jing, ZHANG Ting, HUANG Hui, YANG Dan. Sevaral mechanisms of chemoresistance in chondrosarcoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 176-179.

参考文献

1 姚彦尔,黄正接.软骨肉瘤的治疗进展[J].齐齐哈尔医学院学报,2011,32(4):593-595.
2 Stein U,Shoemaker RH,Schlag PM.MDR1 gene expression:evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas[J].European Journal of Cancer,1996,32(1):86-92.
3 Oosterwijk JGV,Herpers B,Meijer D,et al.Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro:BCL-2 family members cause chemoresistance[J].Annals of Oncology,2012,23(6):1617-1626.
4 Hans G,Hogendoorn PCW,Dijkstra SD,et al.The clinical approach towards chondrosarcoma[J].Oncologist,2008,13(3):320-329.
5 Bovée JVMG,Hogendoorn PCW,Wunder JS,et al.Cartilage tumours and bone development:molecular pathology and possible therapeutic targets[J].Nature Reviews Cancer,2010,10(7):481-488.
6 Wyman JJ,Hornstein AM,Meitner PA,et al.Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines:expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance[J].J Orthop Res,1999,17(6):935-940.
7 Terek RM,Schwartz GK,Devaney K,et al.Chemotherapy and P-glycoprotein expression in chondrosarcoma[J].J Orthop Res,1998,16(5):585-590.
8 Sonneveld P.Multidrug resistance in haematological malignancies[J].J Int Med,2001,249(S741):47-60.
9 Kim DW,Kim KO,Shin MJ,et al.siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells[J].Molecular Cancer,2009,8(1):1-10.
10 丛义梅,刘鹏,金大鹏,等.Bcl-2家族与细胞凋亡的关系[J].中华医学研究杂志,2008,8(2):125-127.
11 David M,Alexandrine L,Amélie B,et al.New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance[J].Laboratory Investigation,2013,93(10):1100-1114.
12 Heymann D,Rdini F.Targeted therapies for bone sarcomas[J].Bonekey Reports,2013,2(2):378-378.
13 Valen FV,Fulda S,Schfer KL,et al.Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs normal human cells[J].International Journal of Cancer,2004,107(6):929-40.
14 Kontny HU,Hmmerle K,Klein R,et al.Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis[J].Cell Death Differ,2001,8(5):506-514.
15 Picarda G,Lamoureux F,Geffroy L,et al.Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth,prevents osteolysis,and increases animal survival[J].Clin Cancer Res,2010,16(8):2363-74.
16 Wang Y,Mandal D,Wang S,et al.Platelet-derived growth factor receptor β inhibition increases tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)sensitivity[J].Cancer,2010,116(16):3892-3902.
17 Van VF,Harrer H,Hotfilder M,et al.A novel role of IGF1 in Apo2L/TRAIL-mediated apoptosis of ewing tumor cells[J].Sarcoma,2012,2012:782970-782970.
18 Holt SV,Brookes KE,Caroline D,et al.Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents[J].Oncology Reports,2011,25(4):1177-1181.
19 Heike A,Boyd DD,Heiss MM,et al.Activation of Src kinase in primary colorectal carcinoma:an indicator of poor clinical prognosis[J].Cancer,2002,94(2):344-351.
20 周文祥,杨永丽,杨晓,等.PI3K/Akt/GSK-3β信号通路在肾小管上皮细胞缺血再灌注损伤中的调控作用及重组人红细胞生成素预保护效应[J].华中科技大学学报:医学版,2010,39(3):314-320.
21 Van Oosterwijk JG,Van Ruler MA,Briaire-de Bruijn IH,et al.Src kinases in chondrosarcoma chemoresistance and migration:dasatinib sensitises to doxorubicin in TP53 mutant cells[J].Br J Cancer,2013,109(5):1214-1222.
22 Li W,Liu W,Zhao Y.PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells[J].Molecular Carcinogenesis,2014,53(5):403-412.
23 Song YD,Zhang KF,Liu D,et al.Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin[J].Tumour Biol,2014,35(7):7017-7024.
24 Hua G,Liu Y,Li X,et al.Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A[J].Oncology Reports,2014,31(6):2727-2734.
25 Zhu Z,Wang CP,Zhang YF,et al.MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR[J].Asian Pac J Cancer Prev,2014,15(2):917-923.

[1]	申美莹, 庞达. 长链非编码RNA在肿瘤微环境中的调控作用[J]. 实用肿瘤学杂志, 2018, 32(1): 73-76.
[2]	任婷婷，邢影，综述，孟庆威，审校. 细胞自噬与肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(6): 543-546.
[3]	孙磊邱玲于雷马岩贾晓晶. 眶内间叶性软骨肉瘤1例[J]. 实用肿瘤学杂志, 2014, 28(4): 342-343.
[4]	张, 波, 刘庆伟, 施红旗, 楼善贤. 透明细胞软骨肉瘤的临床、放射学及病理学特征[J]. 实用肿瘤学杂志, 2008, 22(6): 523-525.
[5]	蒲兴海. 椎间盘部位软骨肉瘤的特点及临床分析[J]. 实用肿瘤学杂志, 2003, 17(04): 303-306.

软骨肉瘤化疗耐药机制

Sevaral mechanisms of chemoresistance in chondrosarcoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价